Literature DB >> 7712286

Coagulation factors and their inhibitors.

M T Stubbs1, W Bode.   

Abstract

A comprehensive three-dimensional picture of the coagulation process is beginning to emerge. Crystallographic structure determinations of prothrombin, factor Xa, factor IXa, tissue factor and factor XIII represent important advances in our understanding of the coagulation cascade. Similarly, structures of antithrombin, tissue factor pathway inhibitor and thrombomodulin provide details of endogenous anticoagulatory mechanisms. NMR spectroscopy of multiple domains of coagulation proteins represents an important contribution to the analysis of flexibility and rigidity of modular proteins. Thrombin, as the prime candidate for antithrombotic drug design, continues to be an object of intense efforts in applied crystallography.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7712286     DOI: 10.1016/0959-440x(94)90263-1

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  9 in total

1.  Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors.

Authors:  T Fox; E E Haaksma
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

2.  Cytomegalovirus assemblin: the amino and carboxyl domains of the proteinase form active enzyme when separately cloned and coexpressed in eukaryotic cells.

Authors:  M R Hall; W Gibson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  Functionality map analysis of the active site cleft of human thrombin.

Authors:  P D Grootenhuis; M Karplus
Journal:  J Comput Aided Mol Des       Date:  1996-02       Impact factor: 3.686

4.  Thermodynamics of single peptide bond cleavage in bovine pancreatic trypsin inhibitor (BPTI).

Authors:  Olga Buczek; Daniel Krowarsch; Jacek Otlewski
Journal:  Protein Sci       Date:  2002-04       Impact factor: 6.725

5.  Cleavage of the thrombin receptor: identification of potential activators and inactivators.

Authors:  M A Parry; T Myles; J Tschopp; S R Stone
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

6.  Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-am idino- 2- naphthyl)propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis.

Authors:  R J Vaz; L R McLean; J T Pelton
Journal:  J Comput Aided Mol Des       Date:  1998-03       Impact factor: 3.686

7.  Production of transgenic goats expressing human coagulation factor IX in the mammary glands after nuclear transfer using transfected fetal fibroblast cells.

Authors:  Amir Amiri Yekta; Azam Dalman; Poopak Eftekhari-Yazdi; Mohammad Hossein Sanati; Abdol Hossein Shahverdi; Rahman Fakheri; Hamed Vazirinasab; Mohammad Taghi Daneshzadeh; Mahdi Vojgani; Alireza Zomorodipour; Nayeralsadat Fatemi; Zeinab Vahabi; Shahab Mirshahvaladi; Fariba Ataei; Elmira Bahraminejad; Najmehsadat Masoudi; Mojtaba Rezazadeh Valojerdi; Hamid Gourabi
Journal:  Transgenic Res       Date:  2012-08-07       Impact factor: 2.788

Review 8.  Vaccine market and production capabilities in the Americas.

Authors:  Esteban Ortiz-Prado; Estefanía Espín; Jorge Vásconez; Nathalia Rodríguez-Burneo; Nikolaos C Kyriakidis; Andrés López-Cortés
Journal:  Trop Dis Travel Med Vaccines       Date:  2021-04-13

9.  Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.

Authors:  Haixin Li; Ying Huang; Xian Wu; Ting Wu; Ying Cao; Qimei Wang; Yuchang Qiu; Weiming Fu; Qun Zhang; Jianxin Pang
Journal:  Drug Des Devel Ther       Date:  2018-05-23       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.